{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:14:11Z","timestamp":1789164851087,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1016\/j.contraception.2007.12.007","type":"journal-article","created":{"date-parts":[[2008,3,13]],"date-time":"2008-03-13T13:50:12Z","timestamp":1205416212000},"page":"337-343","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles) \u2014 an open-label, prospective, noncontrolled, office-based Phase III study"],"prefix":"10.1016","volume":"77","author":[{"given":"Hans Peter","family":"Zahradnik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Hanjalic-Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2007.12.007_bib1","first-page":"1058","article-title":"Recommendations on oral contraception","volume":"38","author":"Bettendorf","year":"1997","journal-title":"Der Frauenarzt"},{"key":"10.1016\/j.contraception.2007.12.007_bib2","series-title":"Die Wirkung der androgene auf das zyklusgeschehen chlormadinonacetat bei androgenisierungserscheinungen","first-page":"43","author":"Mall-Haefeli","year":"1995"},{"key":"10.1016\/j.contraception.2007.12.007_bib3","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/oxfordjournals.humrep.a136950","article-title":"Hirsutism its pathogenesis","volume":"4","author":"Breckwoldt","year":"1989","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2007.12.007_bib4","series-title":"Hirsutism","first-page":"777","author":"Breckwoldtt","year":"1990"},{"key":"10.1016\/j.contraception.2007.12.007_bib5","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1055\/s-2008-1036324","article-title":"Effect of a new hormonal contraceptive (Neo-eunomin) in females with androgenization symptoms","volume":"44","author":"Kaiser","year":"1984","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"10.1016\/j.contraception.2007.12.007_bib6","series-title":"Chemie und pharmakologie von chlormadinonacetat chlormadinonacetat bei androgenisierungserscheinungen","first-page":"1","author":"Kuhl","year":"1995"},{"key":"10.1016\/j.contraception.2007.12.007_bib7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0010-7824(93)90141-S","article-title":"Hemostatic and metabolic effects of lowering the ethinyl-estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel","volume":"48","author":"Basdevant","year":"1993","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2007.12.007_bib8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2165\/00044011-200222040-00002","article-title":"Contraceptive efficacy and tolerability of chlormadinone acetate 2 mg\/ethinylestradiol 0.03 mg (Belara\u00ae). Results of a post-marketing surveillance study","volume":"22","author":"Schramm","year":"2002","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.contraception.2007.12.007_bib9","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0010-7824(02)00536-X","article-title":"A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties","volume":"67","author":"Schramm","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2007.12.007_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0010-7824(98)00008-0","article-title":"Efficacy and safety of the new antiandrogenic oral contraceptive Belara","volume":"57","author":"Zahradnik","year":"1998","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2007.12.007_bib11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000051701","article-title":"Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE\/CMA (Belara) and EE\/LNG (Microgynon)","volume":"203","author":"Worret","year":"2001","journal-title":"Dermatology"},{"key":"10.1016\/j.contraception.2007.12.007_bib12","first-page":"263","article-title":"Contraception and fertility in 2000 women","volume":"4","author":"Pearl","year":"1932","journal-title":"Hum Biol"},{"key":"10.1016\/j.contraception.2007.12.007_bib13","series-title":"Gyn\u00e4kologische endokrinologie","author":"Runnebaum","year":"1994"},{"key":"10.1016\/j.contraception.2007.12.007_bib14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/13625180008500375","article-title":"Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone","volume":"5","author":"Huber","year":"2000","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2007.12.007_bib15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0010-7824(00)00083-4","article-title":"An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen","volume":"61","author":"Parsey","year":"2000","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2007.12.007_bib16","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0010-7824(01)00235-9","article-title":"Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 mcg ethinyl estradiol and 75 mcg gestodene and a 21-day regimen with 20 mcg ethinyl estradiol and 150 mcg desogestrel","volume":"64","author":"Endrikat","year":"2001","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2007.12.007_bib17","first-page":"1034","article-title":"Evaluation of a new generation of oral contraceptives. The Advisory Board for the New Progestins","volume":"81","author":"Speroff","year":"1993","journal-title":"Obstet Gynecol"},{"issue":"Suppl 3","key":"10.1016\/j.contraception.2007.12.007_bib18","first-page":"117","article-title":"Clinical review of a monophasic oral contraceptive containing desogestrel and ethinyl estradiol","volume":"38","author":"Stone","year":"1993","journal-title":"Int J Fertil Menopausal Stud"},{"key":"10.1016\/j.contraception.2007.12.007_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0010-7824(94)00010-T","article-title":"Twelve years of clinical experience with an oral contraceptive containing 30 micrograms ethinylestradiol and 150 micrograms desogestrel","volume":"51","author":"Fotherby","year":"1995","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2007.12.007_bib20","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/13625180008500387","article-title":"A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel","volume":"5","author":"Foidart","year":"2000","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2007.12.007_bib21","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/0002-9378(69)90142-2","article-title":"Incidence of side effects with contraceptive placebo","volume":"105","author":"Aznar-Ramos","year":"1969","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2007.12.007_bib22","first-page":"180","article-title":"Clinical relevance of plasma lipid changes during use of new low-dose oral contraceptives","volume":"7","author":"Gaspard","year":"1991","journal-title":"Adv Contracept"},{"issue":"3 Pt 1","key":"10.1016\/j.contraception.2007.12.007_bib23","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0002-9378(98)70047-X","article-title":"Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons","volume":"179","author":"Rosenberg","year":"1998","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2007.12.007_bib24","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.contraception.2007.03.014","article-title":"Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study","volume":"76","author":"Schramm","year":"2007","journal-title":"Contraception"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782408000097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782408000097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T03:18:27Z","timestamp":1557371907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782408000097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S0010782408000097"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2007.12.007","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}